10 High Growth Stocks to Buy Now in 2026

The investment landscape through late 2025 has demonstrated remarkable resilience, with the S&P 500 advancing more than 20% annually and maintaining its bull market momentum. As we enter 2026, identifying high growth stocks to buy now remains a critical strategy for portfolio building. The market surge has been powered by technological innovation, particularly the artificial intelligence revolution, coupled with investor enthusiasm around potential interest rate improvements. Understanding which high growth stocks to buy now requires examining companies positioned at the intersection of transformative trends and proven market strength.

Market Tailwinds Driving High Growth Investment Opportunities

The past three years through late 2025 have rewarded investors who positioned themselves in sectors benefiting from structural change. The S&P 500’s consistent double-digit annual performance reflects not random market enthusiasm, but fundamental shifts in technology adoption, healthcare innovation, and consumer behavior. High growth stocks to buy now are those capturing these secular trends. History demonstrates that bull markets typically persist longer than their bearish counterparts, suggesting there remains substantial runway for equity appreciation. This environment makes careful stock selection essential—identifying companies that can sustain expansion while weathering potential economic headwinds.

Technology Leaders Capturing the AI Transformation

Nvidia stands as the foundational player in artificial intelligence infrastructure. The world’s leading AI chip designer has benefited from explosive demand for compute capacity, with earnings expansion potentially only in its early stages. The anticipated multi-trillion-dollar investment cycle in AI infrastructure over the coming years positions this technology titan advantageously. As AI models increasingly depend on advanced chips for deployment across real-world applications, Nvidia shareholders can reasonably anticipate sustained momentum. This represents a quintessential high growth stock worth considering for 2026 portfolios.

Meta Platforms presents a compelling contrarian opportunity among the Magnificent Seven technology stocks. Trading at 26x forward earnings estimates—meaningfully cheaper than peers—Meta combines established earnings growth with aggressive artificial intelligence development. The company’s investment in building proprietary large language models and virtual assistants demonstrates commitment to competitive positioning in the AI era. For investors seeking high growth stocks to buy now with established profitability plus transformation upside, Meta merits serious consideration.

CoreWeave exemplifies pure-play AI infrastructure exposure. This company provides the specialized computing capacity that artificial intelligence customers require most urgently. Having climbed over 300% from its March launch through June 2025 before consolidating, CoreWeave’s business model of renting high-performance computing resources directly benefits from accelerating AI workload deployment. The revenue trajectory suggests substantial 2026 expansion potential, making this a legitimate high growth stock for investors comfortable with newer public companies.

Amazon combines establishment credibility with genuine growth catalysts. Beyond its e-commerce dominance, Amazon Web Services generates $132 billion in annual revenue with continued acceleration fueled by artificial intelligence optimization. The cloud division’s expansion, combined with AI-driven efficiency improvements across the broader business, positions this company advantageously at a reasonable 32x forward earnings valuation. For portfolios requiring established market giants capable of meaningful appreciation, Amazon qualifies as a foundational high growth stock to buy now.

Healthcare Innovation: Weight Loss Therapeutics and Insurance Solutions

Eli Lilly has established commanding momentum in the weight loss pharmaceutical market through its Tirzepatide portfolio—marketed as Mounjaro for type 2 diabetes and Zepbound for weight management. Blockbuster revenue generation has powered double-digit company revenue expansion. The company’s recently disclosed phase 3 results for oral candidate orforglipron signal imminent commercialization, potentially adding another growth lever to an already thriving weight loss franchise. This healthcare player exemplifies the combination of safety and growth potential that sophisticated investors seek.

Viking Therapeutics represents the emerging competitor opportunity within the expanding weight loss market. With injectable and oral candidates demonstrating promising phase 3 and phase 2 results respectively, Viking pursues comparable mechanisms to market leaders while addressing a market where demand significantly exceeds current supply. Market share fragmentation appears inevitable, and early positioning in genuine clinical contenders may reward patient investors. This positions Viking as a high growth stock to buy now for those comfortable with clinical-stage risk.

Abbott Laboratories provides growth through stability. This Dividend King—having increased distributions for over 50 consecutive years—demonstrates operational excellence and financial discipline. Diversification across medical devices, diagnostics, nutrition, and established pharmaceuticals creates natural hedging against sector-specific headwinds. Industry-leading products including the FreeStyle Libre glucose monitor and Ensure nutrition franchise generate reliable cash generation. For investors balancing high growth ambitions with portfolio stability, Abbott merits consideration.

UnitedHealth Group presents a recovery narrative. The nation’s largest health insurer addressed recent earnings pressures through operational discipline—including plan optimization and AI-driven efficiency initiatives. Early fruit from these efforts manifested in raised full-year guidance, suggesting inflection toward renewed expansion. At 20x forward earnings, the valuation appears reasonable relative to industry leadership position and long-term expansion potential, making this health services leader attractive for recovery-focused allocations.

Consumer Growth: Brand Loyalty and E-Commerce Convenience

Chewy has built defensible competitive moat through customer loyalty and subscription convenience. The company’s AutoShip program—accounting for over 80% of net sales—provides revenue visibility while embedding switching costs that protect market position. Profitability combined with zero debt strengthens the balance sheet and provides capital flexibility for strategic opportunities. This e-commerce leader represents accessible exposure to consumer subscription trends with tangible competitive advantages.

American Express serves affluent consumers whose spending patterns prove resilient across economic cycles. Growing millennial and Gen-Z membership—comprising 64% of new accounts in recent quarters—demonstrates capability to refresh customer base while maintaining core affluent positioning. This payments processor combines defensive characteristics of established market dominance with growth potential from market expansion among younger cohorts.

Building 2026 Portfolios with High Growth Stocks to Buy Now

Constructing a balanced portfolio demands incorporating multiple growth vectors while maintaining downside protection. The stocks identified span technology innovation, healthcare advancement, and established consumer franchises—collectively representing high growth stocks to buy now across varied risk profiles and market environments. Your investment approach should reflect personal time horizon, risk tolerance, and specific financial objectives while recognizing that market history supports sustained bull market performance for investors maintaining appropriate exposure. The opportunity presented by high growth stocks in 2026 remains substantial for those exercising disciplined selection and patient capital deployment.